POMT1

Across TCGA pan-cancer cohorts, POMT1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated POMT1 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher POMT1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated POMT1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, PAAD, and PRAD are the cancer types where POMT1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.153	0.835	<.001	42	view →
PAAD	DFS	Median	All	0.060	0.484	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	III,IV	1.000	0.542	.043	6	view →
SKCM	OS	Median	All	0.218	0.327	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

POMT1–LUAD (OS)

Open the LUAD breakdown →